Padeliporfin for untreated localised prostate cancer (Single Technology Assessment)
As part of the NICE single technology appraisal process, the Aberdeen evidence review group (ERG) was asked to critically review the company’s submission related to the clinical and cost-effectiveness of Padeliporfin for the treatment of untreated, unilateral, low-risk prostate cancer in adults.
Outcome and Translation
Based on consideration of evidence submitted by the company and the review submitted by the Aberdeen Evidence Review Group, NICE decided not to recommend Padeliporfin for this treatment indication. Details of the NICE appraisal committees’ consideration of the evidence can be found here: Padeliporfin for untreated localised prostate cancer. Technology appraisal guidance [TA546].
HERU researchers involved in this research project: Graham Scotland,
External collaborators: Ramsay, C., Brazzelli, M; Campbell, M. (Health Services Research Unit (HSRU), University of Aberdeen).
Scotland, G., Dimitrova, M., Ayansina, D., Cruickshank, M., Imamura, M., Fraser, C., Lam, T. and Brazelli, M. (2018) Padeliporfin for treating localised prostate cancer, (NICE Technology Appraisal Guidance - TA546), Aberdeen Health Technology Assessment Group.